Completed PHASE1 INTERVENTIONAL NCT00000652
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
Sponsor: National Cancer Institute (NCI)
Conditions
HIV Infections
Interventions
Didanosine Zidovudine
Updated 5 times since 2017 Last updated: Oct 31, 2012 Completion: Nov 30, 1995
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1 clinical study on HIV Infections, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- National Cancer Institute (NCI)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .